AN2 Therapeutics-AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease

新会话

CtrlI

AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease

AN2 Therapeutics(ANTX) Businesswire·2024-02-12 19:45

AN2 Therapeutics公司最新动态 - AN2 Therapeutics, Inc.宣布自愿暂停第3阶段的招募，以进一步评估数据[1] - 独立的数据安全监控委员会将进行非盲目评估并推荐下一步措施[2] - AN2 Therapeutics公司计划在2024年第二季度提供有关epetraborole Phase 2/3临床试验的更多细节[3]